NO20022442D0 - Legemidler for sykdommer i forbindelse med reduksjon i benmasse - Google Patents
Legemidler for sykdommer i forbindelse med reduksjon i benmasseInfo
- Publication number
- NO20022442D0 NO20022442D0 NO20022442A NO20022442A NO20022442D0 NO 20022442 D0 NO20022442 D0 NO 20022442D0 NO 20022442 A NO20022442 A NO 20022442A NO 20022442 A NO20022442 A NO 20022442A NO 20022442 D0 NO20022442 D0 NO 20022442D0
- Authority
- NO
- Norway
- Prior art keywords
- bone mass
- medicines
- reduction
- diseases related
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33349099 | 1999-11-24 | ||
JP2000056534 | 2000-03-01 | ||
JP2000119188 | 2000-04-20 | ||
PCT/JP2000/008235 WO2001037877A1 (fr) | 1999-11-24 | 2000-11-22 | Medicaments pour des affections liees a la perte de masse osseuse |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022442D0 true NO20022442D0 (no) | 2002-05-23 |
NO20022442L NO20022442L (no) | 2002-07-24 |
Family
ID=27340604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022442A NO20022442L (no) | 1999-11-24 | 2002-05-23 | Legemidler for sykdommer i forbindelse med reduksjon i benmasse |
Country Status (16)
Country | Link |
---|---|
US (1) | US6891062B2 (no) |
EP (1) | EP1232757B1 (no) |
JP (1) | JP3705360B2 (no) |
KR (1) | KR100654653B1 (no) |
CN (1) | CN1262309C (no) |
AT (1) | ATE452640T1 (no) |
AU (1) | AU783939B2 (no) |
CA (1) | CA2391526A1 (no) |
DE (1) | DE60043587D1 (no) |
ES (1) | ES2337333T3 (no) |
HU (1) | HUP0203590A3 (no) |
MX (1) | MXPA02005173A (no) |
NO (1) | NO20022442L (no) |
NZ (1) | NZ519101A (no) |
TW (1) | TWI247606B (no) |
WO (1) | WO2001037877A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04000454A (es) * | 2001-07-16 | 2004-03-18 | Hoffmann La Roche | Derivados de 2-pirrolidona como agonistas de prostanoides. |
ATE500218T1 (de) * | 2001-07-23 | 2011-03-15 | Ono Pharmaceutical Co | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff |
CA2467061A1 (en) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient |
CA2485485A1 (en) * | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
EP1878741A3 (en) * | 2002-05-23 | 2008-02-20 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
JPWO2006075690A1 (ja) * | 2005-01-14 | 2008-06-12 | 小野薬品工業株式会社 | 安定な医薬組成物 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
JPWO2006118173A1 (ja) | 2005-04-28 | 2008-12-18 | 小野薬品工業株式会社 | 経皮吸収製剤 |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
EP3424507A1 (en) | 2006-03-24 | 2019-01-09 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
EP3824885A1 (en) * | 2006-10-20 | 2021-05-26 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
KR20090075864A (ko) * | 2006-10-26 | 2009-07-09 | 오노 야꾸힝 고교 가부시키가이샤 | 첨부제 |
US8507545B2 (en) * | 2007-05-08 | 2013-08-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
WO2009155041A2 (en) * | 2008-05-28 | 2009-12-23 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
ES2824842T3 (es) | 2009-07-13 | 2021-05-13 | Patheon Api Services Inc | Síntesis de prostanoides |
CN112410298A (zh) | 2011-12-02 | 2021-02-26 | 菲特治疗公司 | 增强的干细胞组合物 |
JP6106688B2 (ja) | 2011-12-02 | 2017-04-05 | フェイト セラピューティクス,インコーポレイテッド | 虚血を処置する改善された方法 |
JP6141430B2 (ja) | 2012-07-19 | 2017-06-07 | ケイマン ケミカル カンパニー, インコーポレーテッド | Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物 |
AU2014228973B2 (en) | 2013-03-15 | 2018-11-08 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
KR102311896B1 (ko) | 2013-09-30 | 2021-10-14 | 패턴 에이피아이 서비시즈 인코포레이티드 | 복분해를 사용하는 프로스타글란딘 및 프로스타글란딘 중간체의 합성 경로 |
JP2018536017A (ja) | 2015-09-22 | 2018-12-06 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための化合物及び組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0951282B1 (en) * | 1996-12-20 | 2008-04-02 | Pfizer Inc. | Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists |
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
US6043275A (en) * | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
EP1114816A4 (en) | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT |
EP1121133A1 (en) * | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
-
2000
- 2000-11-17 TW TW089124347A patent/TWI247606B/zh not_active IP Right Cessation
- 2000-11-22 KR KR1020027006572A patent/KR100654653B1/ko not_active IP Right Cessation
- 2000-11-22 NZ NZ519101A patent/NZ519101A/en unknown
- 2000-11-22 CN CNB008186340A patent/CN1262309C/zh not_active Expired - Fee Related
- 2000-11-22 AU AU15485/01A patent/AU783939B2/en not_active Ceased
- 2000-11-22 ES ES00977860T patent/ES2337333T3/es not_active Expired - Lifetime
- 2000-11-22 JP JP2001539491A patent/JP3705360B2/ja not_active Expired - Fee Related
- 2000-11-22 DE DE60043587T patent/DE60043587D1/de not_active Expired - Lifetime
- 2000-11-22 WO PCT/JP2000/008235 patent/WO2001037877A1/ja not_active Application Discontinuation
- 2000-11-22 AT AT00977860T patent/ATE452640T1/de not_active IP Right Cessation
- 2000-11-22 HU HU0203590A patent/HUP0203590A3/hu unknown
- 2000-11-22 CA CA002391526A patent/CA2391526A1/en not_active Abandoned
- 2000-11-22 EP EP00977860A patent/EP1232757B1/en not_active Expired - Lifetime
- 2000-11-22 MX MXPA02005173A patent/MXPA02005173A/es active IP Right Grant
-
2002
- 2002-05-23 NO NO20022442A patent/NO20022442L/no not_active Application Discontinuation
-
2004
- 2004-05-13 US US10/844,404 patent/US6891062B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3705360B2 (ja) | 2005-10-12 |
NO20022442L (no) | 2002-07-24 |
KR100654653B1 (ko) | 2006-12-07 |
CN1262309C (zh) | 2006-07-05 |
ES2337333T3 (es) | 2010-04-23 |
NZ519101A (en) | 2004-04-30 |
WO2001037877A1 (fr) | 2001-05-31 |
CA2391526A1 (en) | 2001-05-31 |
AU1548501A (en) | 2001-06-04 |
HUP0203590A2 (hu) | 2003-03-28 |
KR20020059774A (ko) | 2002-07-13 |
ATE452640T1 (de) | 2010-01-15 |
HUP0203590A3 (en) | 2006-07-28 |
DE60043587D1 (de) | 2010-02-04 |
AU783939B2 (en) | 2006-01-05 |
EP1232757B1 (en) | 2009-12-23 |
MXPA02005173A (es) | 2004-02-26 |
CN1424918A (zh) | 2003-06-18 |
US20040209848A1 (en) | 2004-10-21 |
US6891062B2 (en) | 2005-05-10 |
EP1232757A4 (en) | 2004-06-16 |
TWI247606B (en) | 2006-01-21 |
EP1232757A1 (en) | 2002-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20022442L (no) | Legemidler for sykdommer i forbindelse med reduksjon i benmasse | |
WO2003000343A3 (en) | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | |
DE69732170D1 (de) | Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan | |
BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
MXPA04005790A (es) | Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona. | |
NZ514574A (en) | Novel method of treatment | |
TW200505901A (en) | Muscarinic agonists | |
AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
HUP0600140A3 (en) | Prostaglandine derivatives for the treatment of diseases with bone mass loss having ep4 agonist activity and pharmaceutical compositions thereof | |
BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
DE50012571D1 (de) | Biotin enthaltende galenische formulierung | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
ATE324112T1 (de) | Topische behandlung bei der mastalgie | |
HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
WO2001074396A8 (en) | Composition and method for promoting oral health | |
BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
HUP9802716A2 (hu) | Fájdalomcsillapító gyógyszerkombináció | |
DK1209166T3 (da) | Hidtil ukendte A-500 359-derivater | |
SE0000303D0 (sv) | Novel compounds | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
SE0203817D0 (sv) | New composition | |
WO2001007029A3 (en) | Substituted guanidines and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |